| 1 |
NCT00792636 |
Completed
Has Results |
A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period |
|
- Drug: sumatriptan and naproxen sodium combination tablet
- Drug: sumatriptan tablet
- Drug: naproxen sodium tablet
|
Interventional
|
Phase 4 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan/Naproxen
- Mean Change From Baseline in Systolic and Diastolic Blood Pressure at Month 6 for Sumatriptan and Naproxen
- Treatment Difference in Systolic and Diastolic Blood Pressure Mean Changes From Baseline at 6 Months Between Sumatriptan/Naproxen and Sumatriptan
- (and 12 more...)
|
407 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00792636 |
110948 |
|
November 2008 |
November 2009 |
November 2009 |
November 18, 2008 |
November 23, 2016 |
November 4, 2010 |
- GSK Investigational Site
Chandler, Arizona, United States - GSK Investigational Site
Gilbert, Arizona, United States - GSK Investigational Site
Litchfield Park, Arizona, United States - (and 46 more...)
|
|
| 2 |
NCT01952574 |
Active, not recruiting
Has Results |
A Phase 2 Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention |
|
- Drug: Erenumab
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Change From Baseline in Monthly Migraine Days at Week 12
- Percentage of Participants With at Least a 50% Reduction From Baseline in Monthly Migraine Days at Week 12
- Change From Baseline in Monthly Migraine Attacks at Week 12
|
483 |
All |
18 Years to 60 Years (Adult) |
NCT01952574 |
20120178
2012-005331-90 |
|
August 6, 2013 |
September 25, 2014 |
November 11, 2019 |
September 30, 2013 |
November 15, 2018 |
July 10, 2018 |
- Research Site
Phoenix, Arizona, United States - Research Site
Long Beach, California, United States - Research Site
National City, California, United States - (and 63 more...)
|
|
| 3 |
NCT01125774 |
Completed
Has Results |
Telcagepant for Prevention of Menstrually Related Migraine in Female Participants With Episodic Migraine (MK-0974-065) |
|
- Drug: Telcagepant
- Drug: Placebo
|
Interventional
|
Phase 2
Phase 3 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of Participants With Clinical Adverse Events (AEs)
- Number of Participants Who Discontinued Study Due to a Clinical AE
- Number of Participants With Laboratory AEs
- (and 6 more...)
|
4548 |
Female |
18 Years and older (Adult, Older Adult) |
NCT01125774 |
0974-065
2010_535 |
|
June 1, 2010 |
April 8, 2011 |
April 8, 2011 |
May 18, 2010 |
October 23, 2018 |
October 3, 2014 |
|
|
| 4 |
NCT02456740 |
Completed
Has Results |
Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Migraine Prevention |
|
- Drug: Erenumab
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline in Mean Monthly Migraine Days to the Last 3 Months of the Double-blind Treatment Period
- Percentage of Participants With at Least a 50% Reduction From Baseline in Monthly Migraine Days in the Last 3 Months of the Double-blind Treatment Phase
- Change From Baseline in Monthly Acute Migraine-specific Medication Treatment Days to the Last 3 Months of the Double-blind Treatment Period
- (and 2 more...)
|
955 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02456740 |
20120296
2014-004464-38 |
STRIVE |
July 17, 2015 |
September 5, 2016 |
June 19, 2017 |
May 28, 2015 |
November 29, 2018 |
July 10, 2018 |
- Research Site
Phoenix, Arizona, United States - Research Site
Anaheim, California, United States - Research Site
Encino, California, United States - (and 126 more...)
|
|
| 5 |
NCT00806546 |
Completed
Has Results |
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months |
|
|
Interventional
|
Phase 3 |
- NuPathe Inc.
- Teva Pharmaceutical Industries
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Subject Self-examination of Skin Irritation
|
514 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00806546 |
PROT-15-NP101-009 |
NP101-009 |
February 2009 |
May 2011 |
May 2011 |
December 11, 2008 |
February 4, 2016 |
March 20, 2013 |
- Phoenix, Arizona, United States
- Scottsdale, Arizona, United States
- Irvine, California, United States
- (and 28 more...)
|
|
| 6 |
NCT01151787 |
Terminated |
Efficacy and Safety of Cyclobenzaprine Hydrochloride Extended Release for the Treatment of Chronic Migraine |
|
- Drug: cyclobenzaprine hydrochloride
- Drug: placebo
|
Interventional
|
Phase 3 |
- Kennedy Medical Group
- Teva Pharmaceuticals USA
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Mean total number of migraine/migrainous headache days per month
- Mean total number of headache days/month
- mean peak daily and mean average daily pain intensity ratings/month
- mean total number of abortive treatment days/month
|
35 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01151787 |
CEPH03242010 |
|
July 2010 |
September 2013 |
September 2013 |
June 28, 2010 |
July 25, 2014 |
|
- The Headache Center at Kennedy Health Alliance
Cherry Hill, New Jersey, United States
|
|
| 7 |
NCT00792103 |
Completed
Has Results |
An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months |
|
|
Interventional
|
Phase 3 |
- NuPathe Inc.
- Teva Pharmaceutical Industries
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Subject Self-examination of Skin Irritation
- Pain Relief
- Nausea Free
- (and 2 more...)
|
198 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00792103 |
PROT-15-NP101-008 |
NP101-008 |
January 2009 |
September 2010 |
September 2010 |
November 17, 2008 |
February 4, 2016 |
May 7, 2013 |
- Phoenix, Arizona, United States
- Little Rock, Arkansas, United States
- Newport Beach, California, United States
- (and 31 more...)
|
|
| 8 |
NCT03732638 |
Recruiting |
Efficacy and Safety Trial of Rimegepant for Migraine Prevention in Adults |
|
- Drug: Rimegepant
- Drug: Placebo
|
Interventional
|
Phase 2
Phase 3 |
- Biohaven Pharmaceuticals, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Change from baseline in mean number of migraine days per month
- Achievement of at least a 50% reduction from baseline in mean monthly migraine days.
- The mean number of rescue medication days per month.
- (and 4 more...)
|
1200 |
All |
18 Years and older (Adult, Older Adult) |
NCT03732638 |
BHV3000-305 |
|
November 14, 2018 |
September 30, 2019 |
February 15, 2020 |
November 6, 2018 |
January 9, 2019 |
|
- MedPharmics, LLC
Phoenix, Arizona, United States - Tucson Neuroscience Research
Tucson, Arizona, United States - Baptist Health Center for Clinical Research
Little Rock, Arkansas, United States - (and 72 more...)
|
|
| 9 |
NCT02066415 |
Completed
Has Results |
A Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) in Chronic Migraine Prevention |
- Treatment for Prevention of Chronic Migraine
|
- Biological: Erenumab
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Change From Baseline in Monthly Migraine Days
- Percentage of Participants With at Least a 50% Reduction in Monthly Migraine Days From Baseline
- Change From Baseline in Monthly Acute Migraine-specific Medication Treatment Days
- (and 3 more...)
|
667 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02066415 |
20120295
2013-001707-36 |
|
March 5, 2014 |
February 24, 2016 |
April 28, 2016 |
February 19, 2014 |
June 21, 2018 |
June 21, 2018 |
- Research Site
La Jolla, California, United States - Research Site
Newport Beach, California, United States - Research Site
San Francisco, California, United States - (and 71 more...)
|
|
| 10 |
NCT02630459 |
Active, not recruiting |
A Safety and Efficacy Study to Evaluate AMG 334 in Migraine Prevention |
|
- Drug: AMG 334 Dose Level 1
- Drug: Placebo
- Drug: AMG 334 Dose Level 2
- Drug: AMG 334 Dose Level 3
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Prevention
|
- Change from baseline in mean monthly migraine days
- Proportion of subjects with at least a 50% reduction from baseline in mean monthly migraine days
- Change from baseline in acute migraine-specific medication treatment days
|
475 |
All |
20 Years to 65 Years (Adult, Older Adult) |
NCT02630459 |
20120309 |
|
January 6, 2016 |
September 25, 2017 |
June 3, 2019 |
December 15, 2015 |
December 6, 2017 |
|
- Research Site
Kamogawa-shi, Chiba, Japan - Research Site
Saijo-shi, Ehime, Japan - Research Site
Ota-shi, Gunma, Japan - (and 41 more...)
|
|
| 11 |
NCT03303092 |
Recruiting |
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Episodic Migraine |
|
- Drug: TEV-48125
- Drug: Placebos
|
Interventional
|
Phase 2
Phase 3 |
- Otsuka Pharmaceutical Co., Ltd.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Mean change from baseline in the monthly (28-day) average number of migraine days during the 12-week period after the first dose of Interventional Medicinal Product
- Proportion of patients reaching at least 50% reduction in the monthly average number of migraine days
- Mean change from baseline in the monthly average number of days of use of any acute migraine medications relative to baseline
- Mean change from baseline in the number of migraine days
|
330 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03303092 |
406-102-00002
JapicCTI-173725 |
|
December 19, 2017 |
June 2019 |
June 2019 |
October 5, 2017 |
December 11, 2018 |
|
|
|
| 12 |
NCT00442221 |
Completed |
The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 Months |
|
- Drug: Sumatriptan and Naproxen sodium
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- END POINTS
- Adverse events, physical examination findings, vital signs and clinical laboratory findings will be evaluated.
|
500 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00442221 |
MT400-303 |
|
May 2004 |
|
August 2004 |
March 1, 2007 |
March 1, 2007 |
|
- POZEN Inc.
Chapel Hill, North Carolina, United States - Headache Wellness Center
Greensboro, North Carolina, United States
|
|
| 13 |
NCT02483585 |
Completed
Has Results |
Study to Evaluate the Efficacy and Safety of Erenumab (AMG 334) Compared to Placebo in Migraine Prevention |
|
- Drug: Erenumab
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline in Monthly Migraine Days at Week 12
- Percentage of Participants With at Least a 50% Reduction From Baseline in Monthly Migraine Days at Week 12
- Change From Baseline in Monthly Acute Migraine-specific Medication Treatment Days at Week 12
- (and 4 more...)
|
577 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02483585 |
20120297
2014-004463-20 |
ARISE |
July 19, 2015 |
July 11, 2016 |
March 20, 2017 |
June 29, 2015 |
November 29, 2018 |
June 25, 2018 |
- Research Site
Birmingham, Alabama, United States - Research Site
Phoenix, Arizona, United States - Research Site
Culver City, California, United States - (and 73 more...)
|
|
| 14 |
NCT02593097 |
Active, not recruiting |
Metformin for the Prevention of Episodic Migraine (MPEM) |
|
- Drug: Metformin
- Drug: Matching Placebo
|
Interventional
|
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- The reduction in the number of migraine days per month during 12 weeks of treatment with metformin vs placebo (primary end point).
- The response rate (percentage of patients with a >50% reduction in migraine days per month) during 12 weeks of treatment with metformin vs placebo (secondary end point).
- Number of participants with treatment-related adverse events
|
40 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02593097 |
15-000422 |
MPEM |
February 2016 |
June 2019 |
June 2019 |
October 30, 2015 |
February 6, 2019 |
|
- Mayo Clinic in Arizona
Scottsdale, Arizona, United States
|
|
| 15 |
NCT03333109 |
Recruiting |
Study of Efficacy and Safety of AMG 334 in Adult Episodic Migraine Patients |
|
- Biological: Erenumab
- Other: Placebo
|
Interventional
|
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Change from baseline in monthly migraine days at the last month (Month 3) of the double-blind treatment period (DBTP)
- Achievement of at least a 50% reduction from baseline in monthly migraine days at Month 3
- Change from Baseline in acute migraine-specific medication treatment days at Month 3
- Change from Baseline in headache impact scores as measured by the HIT-6 at Month 3
|
880 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03333109 |
CAMG334A2302 |
EMPOwER |
February 8, 2018 |
November 15, 2019 |
February 7, 2020 |
November 6, 2017 |
February 12, 2019 |
|
- Novartis Investigative Site
Caba, Buenos Aires, Argentina - Novartis Investigative Site
Caba, Buenos Aires, Argentina - Novartis Investigative Site
Buenos Aires, Argentina - (and 81 more...)
|
|
| 16 |
NCT02074163 |
Unknown † |
ASIS for Botox in Chronic Migraine |
- Chronic Migraine More than15 Days Per Month, and Lasting 4 Hours a Day or Longer.
|
- Drug: Gadolinium
- Drug: Efficacy of Botox intramuscularly at Week 6
- Drug: Efficacy of Botox intramuscularly at Week 12
- (and 10 more...)
|
Interventional
|
Phase 1
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Relative Prolongation Ability Score for Gadolinium subdermally injected.
- Efficacy of Botox intramuscularly vs. subdermally in Chronic Migraine.
|
60 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02074163 |
NCTNS088800
R01NS088800 |
ASISinCM |
January 2016 |
June 2016 |
June 2017 |
February 28, 2014 |
June 24, 2015 |
|
- Automatic Subdermal Injector System, Inc
Westminster, California, United States
|
|
| 17 |
NCT01211795 |
Completed |
Topical Intra-Oral Ketoprofen for Migraine Prevention |
|
- Drug: topical intraoral ketoprofen gel
- Other: Placebo Gel
|
Interventional
|
Phase 3 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Change in number of migraine days per month
- Change in migraine severity
- Change in migraine duration
- Change in headache medication use
|
67 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT01211795 |
IND 79,629 |
|
October 2009 |
June 2011 |
June 2011 |
September 30, 2010 |
June 8, 2011 |
|
- New York Medical College
Valhalla, New York, United States
|
|
| 18 |
NCT02629536 |
Unknown † |
Effect on Migraine Frequency of Combined Anti-oxidant Therapy: The MIGRANT Study. |
|
- Drug: N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet
|
Interventional
|
Phase 3 |
- University of Notre Dame Australia
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Difference in mean number of migraine episodes per month between baseline and final four weeks of the study, for both study groups.
- Difference in mean migraine duration (hours) per month between baseline and final four weeks of the study, for both study groups
- Difference in mean migraine severity score per month (categorical scale; 0 = nil, 1 = mild, 2 = moderate, 3 = severe) between baseline and final four weeks of the study, for both study groups.
- (and 6 more...)
|
90 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02629536 |
Churack Chair |
MIGRANT |
March 2016 |
March 2017 |
March 2017 |
December 14, 2015 |
December 14, 2015 |
|
|
|
| 19 |
NCT03238781 |
Completed |
Study to Evaluate the Efficacy and Safety of AMG 301 in Migraine Prevention |
- Chronic Migraine or Episodic Migraine
|
- Drug: Placebo
- Drug: AMG 301
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Change from the baseline period in monthly migraine days. The monthly migraine days will be calculated using the migraine days over the last 4 weeks of the 12-week double-blind treatment period.
- At least a 50% reduction from the baseline period in monthly migraine days in the last 4 weeks of the 12-week double-blind treatment period
- Change from the baseline period in monthly acute migraine-specific medication days in the last 4 weeks of the 12-week double-blind treatment period.
- (and 2 more...)
|
343 |
All |
18 Years to 60 Years (Adult) |
NCT03238781 |
20150308
2017-000630-57 |
|
September 6, 2017 |
October 16, 2018 |
February 4, 2019 |
August 3, 2017 |
February 6, 2019 |
|
- Research Site
Long Beach, California, United States - Research Site
Santa Monica, California, United States - Research Site
Boulder, Colorado, United States - (and 46 more...)
|
|
| 20 |
NCT03303079 |
Recruiting |
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine |
|
- Drug: TEV-48125
- Drug: Placebo
|
Interventional
|
Phase 2
Phase 3 |
- Otsuka Pharmaceutical Co., Ltd.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Mean change from baseline in the monthly (28-day) average number of headache days of at least moderate severity during the 12-week period after the first dose of Interventional Medicinal Product(IMP)
- Proportion of patients reaching at least 50% reduction in the monthly average number of headache days of at least moderate severity
- Mean change from baseline in the monthly average number of days of use of any acute migraine medications
- (and 2 more...)
|
540 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03303079 |
406-102-00001
JapicCTI-173723 |
|
December 19, 2017 |
June 2019 |
June 2019 |
October 5, 2017 |
December 11, 2018 |
|
|
|
| 21 |
NCT03763058 |
Recruiting |
Music Intervention on Migraine Headaches |
|
|
Interventional
|
Not Applicable |
- Association de Musicothérapie Applications et Recherches Cliniques
- Centre Hospitalier Universitaire de la Réunion
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Frequency of migraine attacks (number of days per month)
- Duration of migraine attacks (hours)
- Intensity of migraine attacks
- (and 2 more...)
|
20 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03763058 |
MusicMig |
CHU |
December 3, 2018 |
March 2019 |
March 2019 |
December 4, 2018 |
December 18, 2018 |
|
- CHU de la Réunion
Saint-Pierre, Réunion
|
|
| 22 |
NCT01071096 |
Completed
Has Results |
Calcitonin Gene-related Peptide Levels in Chronic Migraine |
|
- Drug: OnabotulinumtoxinA
- Drug: Saline
|
Interventional
|
Phase 4 |
- Cady, Roger, M.D.
- Allergan
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change in Number of Headache Days Per Month From Baseline (BL) to Months 1 Through 7.
- Change in Number of Headache Days Per Month From Baseline to Month 1 (M1), Month 1 to Month 2 (M2), and Month 2 to Month 3 (M3).
- Inter-ictal (Baseline) Levels of Saliva Calcitonin Gene-related Peptide (CGRP)
- (and 2 more...)
|
20 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01071096 |
10-001AL |
|
June 2010 |
June 2011 |
June 2011 |
February 19, 2010 |
February 12, 2013 |
February 17, 2012 |
- Clinvest
Springfield, Missouri, United States - Island Neurological Associates, P.C.
Plainview, New York, United States
|
|
| 23 |
NCT02703129 |
Completed |
Nutritional Intervention in Migraine |
|
- Other: Nutritional intervention
|
Interventional
|
Not Applicable |
- Federal University of Minas Gerais
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in clinical parameters of migraine patients by nutritional intervention in the last month.
- Change in clinical parameters of migraine patients by nutritional intervention in the last three month.
- Change in diet quality of migraine patients by nutritional intervention assessed with the Brazilian Healthy Eating Index - Revised (BHEI-R)
- Change in depressive symptoms in migraine patients by nutritional intervention assessed with the Beck Depression Inventory (BDI)
|
52 |
|
Child, Adult, Older Adult |
NCT02703129 |
CAAE 0311.0.203.000-11 |
|
January 2010 |
December 2012 |
December 2012 |
March 9, 2016 |
March 9, 2016 |
|
- Ambulatório Bias Fortes
Belo Horizonte, Minas Gerais, Brazil
|
|
| 24 |
NCT03096834 |
Active, not recruiting |
A Study Evaluating the Effectiveness of AMG 334 Injection in Preventing Migraines in Adults Having Failed Other Therapies |
|
- Biological: Pre-Filled Syringe (PFS)
- Biological: Placebo Pre-Filled Syringe (PFS)
|
Interventional
|
Phase 3 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Percentage of patients with a 50% response in the reduction of Monthly Migraine Days (MMD)
- Change in the number of monthly migraine days (MMDs) from baseline to month 3
- Change in the Migraine Physical Function Impact Diary (MPFID) "impact on everyday activities" domain score from baseline to month 3
- (and 4 more...)
|
247 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03096834 |
CAMG334A2301
2016-002211-18 |
LIBERTY |
March 20, 2017 |
January 18, 2018 |
January 19, 2021 |
March 30, 2017 |
December 25, 2018 |
|
- Novartis Investigative Site
Heidelberg, Australia - Novartis Investigative Site
Innsbruck, Austria - Novartis Investigative Site
Vienna, Austria - (and 64 more...)
|
|
| 25 |
NCT03303105 |
Recruiting |
Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine |
|
|
Interventional
|
Phase 3 |
- Otsuka Pharmaceutical Co., Ltd.
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants with Adverse Events
- Mean change from baseline in the number of migraine days
- Mean change from baseline in the monthly average of migraine days
- (and 2 more...)
|
40 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03303105 |
406-102-00003
JapicCTI-173726 |
|
January 4, 2018 |
February 2020 |
February 2020 |
October 5, 2017 |
February 16, 2018 |
|
|
|
| 26 |
NCT02269553 |
Withdrawn |
TMJ-1001 Bruxism Run-In/Pivotal Trial |
|
- Device: TMJ(TM) NextGeneration
- Device: Standard Hard TMJD Splint
|
Interventional
|
Not Applicable |
- TMJ Health
- Cardiox Corporation
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change from Baseline (CFB) in bruxism episodes per hour of sleep
- CFB in the number of migraine episodes per month
- CFB in the number of headache episodes per month
- (and 4 more...)
|
0 |
All |
18 Years and older (Adult, Older Adult) |
NCT02269553 |
TMJ-1001 |
|
April 2015 |
December 2015 |
December 2015 |
October 21, 2014 |
May 14, 2015 |
|
|
|
| 27 |
NCT02592681 |
Unknown † |
Comparison of the Prophylactic Effect Between Acupuncture and Acupressure on Menstrual Migraine |
|
- Procedure: verum acupuncture
- Procedure: acupressure
- Procedure: control acupuncture
|
Interventional
|
Not Applicable |
- Western University, Canada
|
Other |
- Allocation: Randomized
- Intervention Model: Factorial Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Prevention
|
- change from baseline menstrual migraine attack frequency at 9 months
- change from baseline number of migraine days at 9 months
- change from baseline average visual analogue scale (VAS) at 9 months
- (and 3 more...)
|
120 |
Female |
18 Years to 40 Years (Adult) |
NCT02592681 |
WesternUCanada-acu |
|
November 2015 |
August 2016 |
August 2016 |
October 30, 2015 |
October 30, 2015 |
|
|
|
| 28 |
NCT02578719 |
Withdrawn |
Greater Occipital Nerve (GON) Block Effectivity in the Treatment of Chronic Migraine: 6 Months Follow up |
|
- Drug: bupivacaine
- Drug: saline
|
Interventional
|
Phase 4 |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- 50% decrease in migraine severity
|
0 |
All |
18 Years to 55 Years (Adult) |
NCT02578719 |
B.10.4.ISM.4.06.68.49/ |
GON |
July 2016 |
July 2018 |
July 2018 |
October 19, 2015 |
January 23, 2018 |
|
|
|
| 29 |
NCT03507400 |
Recruiting |
Introvision for Migraine and Headaches |
|
- Behavioral: Introvision: mental and emotional self-regulation
|
Interventional
|
Not Applicable |
- Ludwig-Maximilians - University of Munich
- University of Hamburg
- Introvision e.V
|
Other |
- Allocation: Randomized
- Intervention Model: Sequential Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Number of headache days per month
- Headache intensity
- acute medication per month
- (and 4 more...)
|
80 |
All |
18 Years and older (Adult, Older Adult) |
NCT03507400 |
IntroMig 632-15 |
IntroMig |
September 20, 2017 |
May 2019 |
May 2019 |
April 25, 2018 |
April 25, 2018 |
|
- Hospital of the Ludwig-Maximilians-University
Munich, Bavaria, Germany
|
|
| 30 |
NCT03308968 |
Active, not recruiting |
An Efficacy and Safety Study of Fremanezumab in Adults With Migraine |
|
- Drug: Fremanezumab
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Teva Branded Pharmaceutical Products, R&D Inc.
- Teva Pharmaceutical Industries
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- mean change from baseline in the monthly average number of migraine days during the double-blind period
- proportion of patients reaching at least 50% reduction in the monthly average number of migraine days during the double-blind period
- mean change from baseline in the monthly average number of headache days of at least moderate severity during the double-blind period
- (and 4 more...)
|
838 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03308968 |
TV48125-CNS-30068
2017-002441-30 |
FOCUS |
November 9, 2017 |
October 1, 2018 |
June 6, 2019 |
October 13, 2017 |
February 20, 2019 |
|
- Teva Investigational Site 14742
Huntsville, Alabama, United States - Teva Investigational Site 14729
Long Beach, California, United States - Teva Investigational Site 14739
San Diego, California, United States - (and 110 more...)
|
|
| 31 |
NCT02784847 |
Unknown † |
A Pilot Trial of Triheptanoin for the Preventive Treatment of Migraine |
|
|
Interventional
|
Early Phase 1 |
- University Hospital of Liege
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in monthly migraine days
- Change in mean attack severity
- Change in mean attack duration
- Number of patients who have at least a 50% reduction in monthly migraine days
|
10 |
Female |
18 Years to 65 Years (Adult, Older Adult) |
NCT02784847 |
UX007 |
TRIMI |
June 2016 |
November 2016 |
November 2016 |
May 27, 2016 |
May 27, 2016 |
|
|
|
| 32 |
NCT01450995 |
Completed |
Migraine Treatment Satisfaction With Treximet Versus Concomitant 2 Aleve and Imitrex |
|
- Drug: Treximet
- Drug: Imitrex and two Aleve
|
Interventional
|
Phase 4 |
- Stephen H. Landy, M.D.
- GlaxoSmithKline
- Wesley Headache Clinic
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Measurement of patient satisfaction of Treximet vs 2 Aleve and 100mg Imitrex
- Measurement of time to onset of pain relief
- Measurement of time to onset of pain free
- (and 2 more...)
|
50 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01450995 |
113403 |
|
December 2009 |
May 2011 |
May 2011 |
October 13, 2011 |
October 13, 2011 |
|
- Wesley Headache Clinic
Memphis, Tennessee, United States
|
|
| 33 |
NCT01513291 |
Completed
Has Results |
A Study of the Safety and Efficacy of MK-6096 for Migraine Prophylaxis in Participants With Episodic Migraine (MK-6096-020) |
|
- Drug: MK-6096
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Mean Change From Baseline in Monthly Migraine Days
- Percentage of Participants With One or More Adverse Events
- Percentage of Participants Discontinued From Study Medication Due to an Adverse Event
- (and 3 more...)
|
237 |
All |
18 Years to 64 Years (Adult) |
NCT01513291 |
6096-020 |
|
February 6, 2012 |
October 3, 2012 |
October 3, 2012 |
January 20, 2012 |
November 7, 2018 |
July 20, 2016 |
|
|
| 34 |
NCT02938182 |
Unknown † |
Migraine Prophylaxis With Clopidogrel Trial |
|
|
Interventional
|
Phase 4 |
- First Affiliated Hospital Xi'an Jiaotong University
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change from Baseline Attack Duration of Headache at three months, h
- Change from Baseline Headache Frequency per Month at three months, time
- Change from Baseline Visual Analogue Scale at three months, scores
- (and 2 more...)
|
50 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02938182 |
XJTU1AF-CRS-2016-019 |
|
October 2016 |
October 2017 |
October 2018 |
October 19, 2016 |
October 19, 2016 |
|
- First Affiliated Hospital of Xi'an Jiaotong University
Xi'an, Shaanxi, China
|
|
| 35 |
NCT03076060 |
Completed |
Very Low Calories Ketogenic Diet in Migraine. |
- Migraine
- Overweight and Obesity
|
- Behavioral: Ketogenic diet
- Behavioral: Sham Diet
|
Interventional
|
Not Applicable |
- University of Roma La Sapienza
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Migraine attacks frequency
- Migraine days
- Drug consumption
|
35 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03076060 |
ChEmicrania |
Ketomig |
January 1, 2017 |
September 1, 2017 |
October 23, 2017 |
March 9, 2017 |
October 26, 2017 |
|
- Policlinico Umberto I
Rome, Italy
|
|
| 36 |
NCT03832998 |
Not yet recruiting
New |
Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine |
|
- Drug: Erenumab Dose 1
- Drug: Erenumab Dose 2
- Drug: Erenumab Dose 3
- Other: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline in monthly migraine days (MMDs)
- Change in monthly headache days from baseline
- Proportion of subjects with at least 50% reduction in monthly migraine days (MMDs) from baseline
- (and 4 more...)
|
286 |
All |
6 Years to 17 Years (Child) |
NCT03832998 |
20160354
2017-002399-23 |
OASIS (CM) |
June 6, 2019 |
January 17, 2024 |
September 25, 2024 |
February 6, 2019 |
February 8, 2019 |
|
- Research site
Aurora, Colorado, United States - Research site
Colorado Springs, Colorado, United States - Research site
Washington, District of Columbia, United States - (and 51 more...)
|
|
| 37 |
NCT03836040 |
Not yet recruiting
New |
Efficacy and Safety of Erenumab in Pediatric Subjects With Episodic Migraine |
|
- Drug: Erenumab Dose 1
- Drug: Erenumab Dose 2
- Drug: Erenumab Dose 3
- Other: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline in monthly migraine days (MMDs)
- Change in monthly headache days from baseline
- Proportion of subjects with at least 50% reduction in monthly migraine days (MMDs) from baseline
- (and 4 more...)
|
456 |
All |
6 Years to 17 Years (Child) |
NCT03836040 |
20150125
2017-002397-39 |
OASIS (EM) |
June 6, 2019 |
November 4, 2022 |
June 28, 2023 |
February 11, 2019 |
February 11, 2019 |
|
- Research site
Aurora, Colorado, United States - Research site
Colorado Springs, Colorado, United States - Research site
Washington, District of Columbia, United States - (and 55 more...)
|
|
| 38 |
NCT01775735 |
Terminated
Has Results |
Occipital Nerve Stimulation (ONS) for Migraine: OPTIMISE |
|
- Device: Occipital nerve stimulator
|
Interventional
|
Not Applicable |
- Boston Scientific Corporation
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change in the Number of Moderate-to-severe Headache Days Per Month
|
28 |
All |
21 Years to 75 Years (Adult, Older Adult) |
NCT01775735 |
G120051
CDM00046436 |
OPTIMISE |
April 10, 2013 |
December 1, 2015 |
January 19, 2017 |
January 25, 2013 |
November 2, 2018 |
November 2, 2018 |
- Boston Scientific Clinical Research Information Toll Free Number
Valencia, California, United States
|
|
| 39 |
NCT00799045 |
Unknown † |
Clopidogrel For the Prevention of New Onset Migraine Headache Following Transcatheter Closure of Atrial Septal Defects |
|
|
Interventional
|
Phase 4 |
- Laval University
- Sanofi
- Bristol-Myers Squibb
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Mean number of monthly migraine days per patient within the 3 months following transcatheter ASD closure.
- Severity of migraine attacks following ASD closure as evaluated by the intensity of migraine episodes and the Migraine Disability Assessment (MIDAS) questionnaire at 3-month follow-up after ASD closure.
- Incidence of bleeding complications at 3-month follow-up.
- (and 3 more...)
|
150 |
All |
18 Years and older (Adult, Older Adult) |
NCT00799045 |
CLOPI_L_03563 |
CANOA |
October 2008 |
April 2015 |
April 2016 |
November 27, 2008 |
May 12, 2015 |
|
- Hopital Laval
Quebec, Canada
|
|
| 40 |
NCT02291380 |
Enrolling by invitation |
A Study to Evaluate Botulinum Toxin Type A for Injection（HengLi®）for Prophylactic Treatment of Chronic Migraine |
|
- Drug: Botulinum Toxin Type A for Injection
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Lanzhou Institute of Biological Products Co., Ltd
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline in average number of days with headache per month
- the average number of days with headache per month
- the average frequency of headache per month
- (and 7 more...)
|
288 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02291380 |
HengLi003 |
|
September 2014 |
December 2019 |
June 2020 |
November 14, 2014 |
January 3, 2018 |
|
|
|
| 41 |
NCT03036761 |
Recruiting |
Interest of Auriculotherapy in Prophylaxis of Migraine and Headache in Patients With Migraines |
|
- Procedure: Auriculotherapy
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of days with migraine and non-migraine headache post inclusion.
- Number of days with migraine post inclusion.
- Number of days with non migraine headache post inclusion.
- (and 4 more...)
|
90 |
Female |
18 Months to 80 Years (Child, Adult, Older Adult) |
NCT03036761 |
2016/58
2016-A01534-47 |
Migauric |
January 18, 2017 |
January 18, 2019 |
April 18, 2019 |
January 30, 2017 |
November 1, 2018 |
|
- Cabinet Médical
Maisons-Alfort, France - GHP Saint Joseph
Paris, France - Hopital Foch
Suresnes, France
|
|
| 42 |
NCT02025556 |
Completed |
A Multicenter Assessment of LBR-101 in High Frequency Episodic Migraine |
- Episodic Migraine Headache
|
- Biological: LBR-101 High Dose
- Biological: LBR-101 Low Dose
- Biological: Placebo
|
Interventional
|
Phase 2 |
- Teva Pharmaceutical Industries
- NCGS, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Efficacy of two distinct doses of subcutaneous LBR-101 in the preventive treatment of HFEM, measured by mean change from baseline in the monthly migraine days during the 28-day post treatment period ending with week 12
- Evaluate the safety and tolerability (ie: by measuring the change from baseline in the frequency and severity of adverse events) of LBR-101 in the preventive treatment of HFEM.
- Efficacy of two distinct doses of subcutaneous LBR-101 in the preventive treatment of HFEM, measured by mean change from baseline on the number of days with headache of any severity during the 28-day post treatment period ending with week 12
|
319 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02025556 |
LBR-101-022 |
|
January 2014 |
January 2015 |
March 2015 |
January 1, 2014 |
April 4, 2018 |
|
- Teva Investigational Site 145
Gilbert, Arizona, United States - Teva Investigational Site 117
Scottsdale, Arizona, United States - Teva Investigational Site 158
Little Rock, Arkansas, United States - (and 60 more...)
|
|
| 43 |
NCT02614183 |
Completed
Has Results |
Evaluation of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-1 Study |
|
- Drug: Galcanezumab
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days
- Mean Percentage of Participants With Reduction From Baseline ≥50%, ≥75% and 100% in Monthly Migraine Headache Days
- Mean Change From Baseline in the Migraine-Specific Quality of Life Questionnaire (MSQ) Version 2.1 (v2.1) Role Function Restrictive Domain
- (and 7 more...)
|
862 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02614183 |
15767
I5Q-MC-CGAG |
EVOLVE-1 |
November 30, 2015 |
March 22, 2017 |
August 9, 2018 |
November 25, 2015 |
November 29, 2018 |
November 29, 2018 |
- Territory Neurology & Research Institute
Tucson, Arizona, United States - Orange Grove Family Practice
Tucson, Arizona, United States - Arkansas Clinical Research
Little Rock, Arkansas, United States - (and 92 more...)
|
|
| 44 |
NCT01090050 |
Completed
Has Results |
Treximet in the Treatment of Chronic Migraine |
|
- Drug: Sumatriptan/Naproxen Sodium
- Drug: Naproxen Sodium
|
Interventional
|
Phase 4 |
- Cady, Roger, M.D.
- GlaxoSmithKline
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Percent Change of Migraine Headache Days Compared to Baseline
- Percent Change of Migraine Headache Days in All Treatment Periods Compared to Baseline
- Migraine Headache Duration From Onset to Pain Free
- (and 5 more...)
|
56 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01090050 |
112839 |
|
September 2010 |
June 2012 |
July 2012 |
March 19, 2010 |
July 3, 2013 |
July 3, 2013 |
- Clinvest
Springfield, Missouri, United States - Texas Headache Associates
San Antonio, Texas, United States
|
|
| 45 |
NCT02021773 |
Completed |
Assessment of LBR-101 In Chronic Migraine |
|
- Biological: LBR-101 High Dose
- Biological: LBR-101 Low Dose
- Biological: Placebo
|
Interventional
|
Phase 2 |
- Teva Pharmaceutical Industries
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Mean change from baseline in the number of monthly cumulative headache hours of any severity on headache days relative to the 28-day post-treatment period ending with week 12
- Safety as determined by the presence of Adverse events by treatment group
- Mean change from baseline in the number of headache days of at least moderate severity relative to the 28-day post-treatment period ending with week 12.
|
277 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02021773 |
LBR-101-021 |
|
January 2014 |
February 2015 |
March 2015 |
December 27, 2013 |
April 4, 2018 |
|
- Teva Investigational Site 145
Gilbert, Arizona, United States - Teva Investigational Site 117
Scottsdale, Arizona, United States - Teva Investigational Site 130
Phoenix, Arkansas, United States - (and 53 more...)
|
|
| 46 |
NCT01300546 |
Completed
Has Results |
Treximet Trademark (TM) in the Prevention and Modification of Disease Progression in Migraine |
|
- Drug: Sumatriptan/Naproxen Sodium
- Drug: Naproxen Sodium
|
Interventional
|
Phase 4 |
- Cady, Roger, M.D.
- GlaxoSmithKline
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Percent Change of Headache Days Compared to Baseline
- Migraine Attacks
- Migraine Severity
- (and 9 more...)
|
40 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01300546 |
114933 |
|
December 2010 |
April 2012 |
April 2012 |
February 21, 2011 |
May 21, 2013 |
May 21, 2013 |
- Newport Beach Clinical Research Assoc., Inc.
Newport Beach, California, United States - Clinvest
Springfield, Missouri, United States
|
|
| 47 |
NCT02176018 |
Completed
Has Results |
Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine |
|
- Drug: Dextromethorphan and quinidine
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Cady, Roger, M.D.
- Avanir Pharmaceuticals
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Headache Days in Each Treatment Period Month
- Headache Days in Treatment Period Month 3
- Migraine Days in Each Treatment Period Month
- (and 7 more...)
|
76 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02176018 |
14-001AV |
|
August 2014 |
February 2017 |
March 2017 |
June 26, 2014 |
April 3, 2018 |
April 3, 2018 |
- Swedish American Neuro and Headache Center
Rockford, Illinois, United States - The Headache Center
Ridgeland, Mississippi, United States - StudyMetrix Research, LLC
Saint Peters, Missouri, United States - (and 2 more...)
|
|
| 48 |
NCT03766412 |
Completed |
High School Start Time and Teen Migraine Frequency |
|
- Other: High School start time
|
Observational
|
|
- University of California, San Francisco
|
Other |
- Observational Model: Case-Only
- Time Perspective: Cross-Sectional
|
- Headache days per month
- Hours of sleep on typical school night
- Typical bedtime on school night
- (and 4 more...)
|
256 |
All |
Child, Adult, Older Adult |
NCT03766412 |
High School Start Time Study |
|
October 1, 2018 |
October 15, 2018 |
October 15, 2018 |
December 6, 2018 |
December 6, 2018 |
|
- University of California, San Francisco, (UCSF)
San Francisco, California, United States
|
|
| 49 |
NCT02614261 |
Active, not recruiting
Has Results |
Evaluation of Galcanezumab in the Prevention of Chronic Migraine |
|
- Drug: Galcanezumab
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days (MHD)
- Number of Participants With Reduction From Baseline ≥50%, ≥75% and 100% in Monthly Migraine Headache Days
- Mean Change From Baseline in the Migraine-Specific Quality of Life Questionnaire (MSQ) Role-function Restrictive Domain
- (and 8 more...)
|
1113 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02614261 |
15769
I5Q-MC-CGAI
2015-001883-21 |
REGAIN |
November 30, 2015 |
March 16, 2017 |
May 3, 2021 |
November 25, 2015 |
January 7, 2019 |
January 7, 2019 |
- 21st Century Neurology
Phoenix, Arizona, United States - Arizona Research Center
Phoenix, Arizona, United States - Pharmacology Research Institute, Encino
Encino, California, United States - (and 114 more...)
|
|
| 50 |
NCT02901756 |
Completed |
A Combination of Coenzyme Q10, Feverfew and Magnesium for Migraine Prophylaxis : a Prospective Observational Study |
|
- Dietary Supplement: Antemig
|
Observational
|
|
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- the number of days with migraine headache at the 3rd Month
- Number of days with migraine headache per month
- Intensity of migraine headache evaluated with a 5 points Likert Scale
- (and 5 more...)
|
132 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02901756 |
PiL-Obs-AntMIG-014 |
|
January 2015 |
December 2015 |
December 2015 |
September 15, 2016 |
September 28, 2016 |
|
|
|
| 51 |
NCT01617941 |
Withdrawn |
A Randomized,Double Blind, Placebo Controlled Study to Assess Efficacy,Safety and Tolerability of BGG492 in Migraine Prevention |
- Patients With Migraine Equal of /More Than 3 and Equal of/ Less Than 12 Migraine Attacks/4 Weeks for Each of the Last 6 Months Preceding the Screening
|
- Drug: BGG492
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Frequency of migraine attacks
- Number of migraine attacks
|
0 |
All |
18 Years to 55 Years (Adult) |
NCT01617941 |
CBGG492A2214
2011-005316-28 |
|
May 2016 |
November 2016 |
November 2016 |
June 13, 2012 |
April 20, 2017 |
|
|
|
| 52 |
NCT02021474 |
Unknown † |
A Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Assess the Efficacy and Safety of Subcutaneous Histamine Dihydrochloride for Migraine Prophylaxis |
|
- Drug: Histamine Dihydrochloride
- Drug: Subcutaneous placebo (Evan's solution = phenol 0.4%, isotonic sodium chloride).
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Mean change from baseline in monthly migraine days [time frame: baseline and average over Weeks 3-22].
- Mean change from baseline in monthly migraine days by 4 week intervals [Weeks 3-6, 7-10, 11-14, 15-18, 19-22].
- Mean Change from Baseline in Monthly Migraine Index (MMI)
- Mean change from baseline in monthly number of migraines
|
130 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02021474 |
HSC-201 |
|
September 2015 |
September 2016 |
|
December 27, 2013 |
January 27, 2015 |
|
|
|
| 53 |
NCT00910689 |
Completed
Has Results |
Drug and Non-Drug Treatment Of Severe Migraine |
|
- Drug: Propranolol or nadolol
- Drug: Placebo control
- Behavioral: Behavioral Migraine Management (BMM)
- Drug: Optimal Acute Therapy
|
Interventional
|
Phase 4 |
- Ohio University
- National Institute of Neurological Disorders and Stroke (NINDS)
- Merck Sharp & Dohme Corp.
- GlaxoSmithKline
|
Other / NIH / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in Number of Migraine Episodes Per 30 Days at Month 10.
- Change in the Number of Migraine Days Per 30 Days at Month 10
- Change in Quality of Life at Month 10
- (and 3 more...)
|
232 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00910689 |
2R01NS032374
NS32374 |
TSM |
July 2001 |
November 2005 |
November 2005 |
June 1, 2009 |
November 22, 2016 |
June 1, 2009 |
- Ohio University
Athens, Ohio, United States - OrthoNeuro, Inc.
Westerville, Ohio, United States
|
|
| 54 |
NCT01752439 |
Unknown † |
Effects of Transcranial Direct Current Stimulation in Refractory Chronic Migraine and Medication-overuse Headache |
- Chronic Migraine
- Medication Overuse Headache
|
- Device: Anodal transcranial direct current stimulation
- Device: Sham transcranial direct current stimulation
|
Interventional
|
Not Applicable |
- Dr Armando Perrotta, MD, PhD
- Mediterranean Neurological Institute
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change in headache days per months
- Change in drugs intake per months
- Change in mean pain intensity score per months
|
30 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01752439 |
tDCSCMMOH1 |
|
February 2013 |
December 2013 |
March 2014 |
December 19, 2012 |
December 19, 2012 |
|
|
|
| 55 |
NCT01435941 |
Completed |
Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine |
|
- Drug: Non-steroidal anti-inflammatory drug (NSAID)
- Drug: Triptan
|
Observational
|
|
|
Industry |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Number of participants who progress from EM to CM
|
11249 |
All |
18 Years and older (Adult, Older Adult) |
NCT01435941 |
112630 |
|
September 2009 |
February 2011 |
February 2011 |
September 19, 2011 |
May 16, 2017 |
|
|
|
| 56 |
NCT02725554 |
Not yet recruiting |
Study of Wireless Nerve Stimulation in the Treatment of Chronic Migraine |
|
- Device: StimRelieve Halo System
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Headache Days
- Adverse Events
- Migraine Days
- (and 2 more...)
|
144 |
All |
18 Years and older (Adult, Older Adult) |
NCT02725554 |
30-00070 |
|
January 2019 |
December 2020 |
December 2021 |
April 1, 2016 |
April 19, 2018 |
|
|
|
| 57 |
NCT01686581 |
Completed
Has Results |
An Observational Study of BOTOX® as Headache Prophylaxis for Chronic Migraine |
|
- Drug: botulinum toxin Type A
|
Observational
|
|
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Prospective
|
- Percentage of Participants Admitted to the Hospital for Headache
- Mean Number of Days of Headache-related Hospital Admissions
- Percentage of Participants Who Visited Any Healthcare Professional (HCP)
- (and 5 more...)
|
641 |
All |
18 Years and older (Adult, Older Adult) |
NCT01686581 |
MAF/AGN/NS/CM/002 |
|
July 23, 2012 |
October 12, 2016 |
October 12, 2016 |
September 18, 2012 |
November 9, 2018 |
November 9, 2018 |
- Nicole Strickling
Aachen, Germany - Manfred Oberling
Bad Camberg, Germany - Kathrin Krome
Bamberg, Germany - (and 74 more...)
|
|
| 58 |
NCT00797667 |
Terminated
Has Results |
MK0974 (Telcagepant) for Migraine Prophylaxis in Patients With Episodic Migraine (0974-049) |
|
- Drug: Telcagepant 140 mg
- Drug: Telcagepant 280 mg
- Drug: 140 mg telcagepant placebo
- Drug: 280 mg telcagepant placebo
|
Interventional
|
Phase 2 |
- Merck Sharp & Dohme Corp.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change From Baseline in Mean Monthly Headache Days
- Change From Baseline in Mean Monthly Migraine Days
- Percentage of Participants Who Experienced an Adverse Event
- (and 4 more...)
|
660 |
All |
18 Years and older (Adult, Older Adult) |
NCT00797667 |
0974-049
2008_591 |
|
November 12, 2008 |
May 20, 2009 |
May 20, 2009 |
November 25, 2008 |
October 18, 2018 |
September 8, 2014 |
|
|
| 59 |
NCT02307071 |
Unknown † |
Occipital Transcutaneous Stimulation in Chronic Migraine |
|
- Device: Cefaly Kit Arnold
|
Interventional
|
Phase 4 |
- University Hospital of Liege
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Monthly frequency of migraine days
- Monthly frequency of headache days
- Monthly frequency of total headache days
- (and 2 more...)
|
20 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02307071 |
OTSCM |
OSCRO |
November 2014 |
September 2015 |
December 2015 |
December 3, 2014 |
May 28, 2015 |
|
- CHR Citadelle
Liege, Belgium
|
|
| 60 |
NCT00369499 |
Terminated |
STOP PAIN: Septal Closure of PFO - Does it Prevent Migraine? |
|
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Mean values of the number of monthly migraine periods, with or without aura.
- Mean values of monthly migraine frequency with or without aura.
- Quality of life using a Headache Impact Test Questionnaire.
|
656 |
All |
18 Years to 50 Years (Adult) |
NCT00369499 |
CV05003PC |
|
March 2007 |
|
June 2009 |
August 29, 2006 |
February 25, 2008 |
|
- CardioVascular Center Frankfurt, Sankt Katharinen
Frankfurt, Germany
|
|
| 61 |
NCT02614196 |
Completed
Has Results |
Evaluation of Efficay & Safety of Galcanezumab in the Prevention of Episodic Migraine- the EVOLVE-2 Study |
|
- Drug: Galcanezumab
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Overall Mean Change From Baseline in the Number of Monthly Migraine Headache Days
- Mean Percentage of Participants With Reduction From Baseline ≥50%, ≥75%, and 100% in Monthly Migraine Headache Days
- Mean Change From Baseline in the Migraine-Specific Quality of Life Questionnaire (MSQ) Version 2.1 Role Function Restrictive Domain
- (and 7 more...)
|
986 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02614196 |
15768
I5Q-MC-CGAH
2015‐001882‐17 |
EVOLVE-2 |
December 4, 2015 |
March 29, 2017 |
October 5, 2018 |
November 25, 2015 |
January 7, 2019 |
January 7, 2019 |
- 21st Century Neurology
Phoenix, Arizona, United States - Arizona Research Center
Phoenix, Arizona, United States - Axiom Research
Apple Valley, California, United States - (and 110 more...)
|
|
| 62 |
NCT02848326 |
Completed
Has Results |
Efficacy, Safety, and Tolerability of Multiple Dosing Regimens of Oral Atogepant (AGN-241689) in Episodic Migraine Prevention |
- Migraine, With or Without Aura
|
- Drug: Atogepant
- Drug: Placebo-matching Atogepant
|
Interventional
|
Phase 2
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Change From Baseline in Mean Monthly Migraine Days (Migraine/Probable Migraine Headache Days) Across the 12-Week Treatment Period
- Change From Baseline in Mean Monthly Headache Days Across the 12-Week Treatment Period
- Percentage of Participants With at Least a 50% Reduction in Mean Monthly Migraine Days (Migraine/Probable Migraine Headache Days) Across the 12-Week Treatment Period
- Change From Baseline in Mean Monthly Acute Medication Use Days Across the 12-Week Treatment Period
|
834 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT02848326 |
CGP-MD-01 |
|
September 6, 2016 |
April 2, 2018 |
April 23, 2018 |
July 28, 2016 |
December 6, 2018 |
December 6, 2018 |
- Achieve Clinical Research
Birmingham, Alabama, United States - Radiant Research, Inc.
Chandler, Arizona, United States - The Research Center of Southern California, LLC
Carlsbad, California, United States - (and 72 more...)
|
|
| 63 |
NCT00521196 |
Completed |
Migraine--Investigational Treatment of Migraine With Noninvasive Brain Stimulation. (tDCS- Migraine) |
|
- Device: DC Stimulator (Transcranial Direct Current Stimulator)
|
Interventional
|
Not Applicable |
- Beth Israel Deaconess Medical Center
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Migraine-associated pain (maximum headache intensity)
- Migraine frequency (# of headache days per month)
- Daily average pain
- (and 4 more...)
|
13 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00521196 |
2007P000145 |
|
July 2007 |
January 13, 2012 |
January 13, 2012 |
August 27, 2007 |
March 21, 2017 |
|
- Beth Israel Deaconess Medical Center: Berenson-Allen Center for Noninvasive Brain Stimulation
Boston, Massachusetts, United States
|
|
| 64 |
NCT03812224 |
Not yet recruiting
New |
A Controlled Trial of Erenumab in Migraine Prevention |
|
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Mean Monthly Migraine Days
- 50% reduction in MMD
|
256 |
All |
20 Years to 65 Years (Adult, Older Adult) |
NCT03812224 |
20170609 |
|
April 18, 2019 |
September 22, 2020 |
April 6, 2021 |
January 23, 2019 |
February 7, 2019 |
|
|
|
| 65 |
NCT00772031 |
Completed
Has Results |
NINDS CRC Chronic Migraine Treatment Trial |
|
- Drug: propranolol LA
- Drug: topiramate
- Drug: placebo
|
Interventional
|
Phase 3 |
- Anne Lindblad
- National Institute of Neurological Disorders and Stroke (NINDS)
- Ortho-McNeil Janssen Scientific Affairs, LLC
- The EMMES Corporation
|
Industry / NIH |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Change in the Number of Moderate to Severe Headache Days Within a 28 Day Average Period in Six Months Compared to Baseline
- Number of Subjects Experiencing at Least a 30% Reduction in 28-day Moderate to Severe Headache Days
- Number of Subjects Experiencing at Least a 50% Reduction in 28-day Moderate to Severe Headache Days
- (and 5 more...)
|
191 |
All |
18 Years and older (Adult, Older Adult) |
NCT00772031 |
08-CRC-01
HHSN265200523641C |
CMTT |
October 2008 |
September 2010 |
September 2010 |
October 15, 2008 |
January 24, 2012 |
January 19, 2012 |
- Mayo Clinic 5777 E Mayo Blvd
Phoenix, Arizona, United States - Paradigm Clinical, Inc. 1324 W. Prince Rd
Tuscon, Arizona, United States - Dr. Stephen David Forner - 1405 Magnolia Avenue, Suite B
Chico, California, United States - (and 36 more...)
|
|
| 66 |
NCT01857557 |
Unknown † |
Evaluation of an Aerobic Exercise Program in Migraine Management |
|
|
Interventional
|
Not Applicable |
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Days with headache per month (based on headache diaries),comparing the change from baseline to month 3 and 6 post-randomization in the control versus the intervention group. Migraine Specific Quality of Life Questionnaire scores
- Show Improvement in measures of quality of life,disability,depression,anxiety,and aerobic fitness
|
80 |
All |
18 Years to 58 Years (Adult) |
NCT01857557 |
24702 |
|
August 2012 |
September 2017 |
September 2017 |
May 20, 2013 |
August 18, 2016 |
|
- South Health Campus
Calgary, Alberta, Canada
|
|
| 67 |
NCT00237302 |
Completed |
A Comparison of the Efficacy and Safety of Topiramate Versus Placebo in Preventing Migraine Headaches in Children |
|
|
Interventional
|
Phase 3 |
- Ortho-McNeil Neurologics, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Prevention
|
- Number of migraine days per month (28 days) during the double-blind treatment period relative to the prospective baseline period.
- Monthly rates of migraine episodes, non-migraine headache episodes, and total headache days; percentage of treatment responders; severity and duration of migraines; frequency and severity of associated migraine symptoms, and use of rescue medicines.
|
162 |
All |
6 Years to 15 Years (Child) |
NCT00237302 |
CR002662 |
|
July 2001 |
|
September 2003 |
October 12, 2005 |
May 19, 2011 |
|
|
|
| 68 |
NCT03432286 |
Recruiting |
A Study of Galcanezumab (LY2951742) in Participants 6 to 17 Years of Age With Episodic Migraine |
|
- Drug: Galcanezumab
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Change from Baseline in the Number of Monthly Migraine Headache Days
- Proportion of Participants with Reduction from Baseline ≥50% in Monthly Migraine Headache Days
- Change from Baseline in the Number of Monthly Headache Days with Nausea and/or Vomiting
- (and 13 more...)
|
645 |
All |
6 Years to 17 Years (Child) |
NCT03432286 |
16352
I5Q-MC-CGAS
2017-004351-23 |
REBUILD |
March 14, 2018 |
November 5, 2021 |
November 30, 2022 |
February 14, 2018 |
February 19, 2019 |
|
- Medical Center for Clinical Research
San Diego, California, United States - Clinical Neuroscience Solutions Inc
Jacksonville, Florida, United States - Sensible Healthcare
Ocoee, Florida, United States - (and 13 more...)
|
|
| 69 |
NCT01319825 |
Unknown † |
Preventive Treatment of Episodic and Chronic Migraine |
- Migraine With Aura
- Migraine Without Aura
- Chronic Migraine
|
|
Interventional
|
Phase 4 |
- California Medical Clinic for Headache
|
Other |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Prevention
|
- Reduction in number of all headache days per month in the last month of stable dosing, compared to baseline
- Reduction in number of migraine days per month in the last month of stable dosing compared to baseline.
- Improvement in headache index score
- (and 4 more...)
|
45 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT01319825 |
SAV-MD-26 |
|
April 2011 |
May 2012 |
July 2012 |
March 22, 2011 |
March 22, 2011 |
|
- California Medical Clinic for Headache
Santa Monica, California, United States
|
|
| 70 |
NCT01899040 |
Completed |
A Non-Invasive Neuromodulation Device for Treatment of Migraine Headache |
- Migraine Headache, Episodic
|
- Device: neuromodulation for episodic migraine headache
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of monthly migraine headache days
- Number of monthly migraine headache days (reduction by by 50% or more)
- Total monthly pain score
- (and 5 more...)
|
81 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01899040 |
SNS-MIG-01 |
|
August 2013 |
May 2016 |
June 2016 |
July 15, 2013 |
May 10, 2018 |
|
- Naval Medical Center
San Diego, California, United States - Michigan Headache and Neurological Institute
Ann Arbor, Michigan, United States - Carolina Headache Institute
Chapel Hill, North Carolina, United States - (and 3 more...)
|
|
| 71 |
NCT03559257 |
Active, not recruiting |
A Study of Galcanezumab (LY2951742) in Adults With Treatment-Resistant Migraine |
|
- Drug: Galcanezumab
- Drug: Placebo
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Mean Change from Baseline in the Number of Monthly Migraine Headache Days
- Mean Change from Baseline in the Number of Monthly Migraine Headache Days in Participants with Episodic Migraine
- Percentage of Participants with ≥50% Reduction from Baseline in Monthly Migraine Headache Days
- (and 10 more...)
|
616 |
All |
18 Years to 75 Years (Adult, Older Adult) |
NCT03559257 |
16670
I5Q-MC-CGAW
2018-000600-42 |
CONQUER |
July 31, 2018 |
July 2, 2019 |
October 6, 2019 |
June 18, 2018 |
February 19, 2019 |
|
- 21st Century Neurology
Phoenix, Arizona, United States - Medical Center for Clinical Research
San Diego, California, United States - Sensible Healthcare
Ocoee, Florida, United States - (and 75 more...)
|
|
| 72 |
NCT01081795 |
Completed
Has Results |
A Dose-Finding Study of Topiramate (JNS019) in Participants With Migraine |
|
- Drug: Topiramate
- Drug: Placebo
|
Interventional
|
Phase 2 |
- Janssen Pharmaceutical K.K.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Mean Change From Baseline in Monthly Migraine Attacks (According to 24-Hour Rule) Through Month 6
- Change From Baseline in Average Number of Monthly Migraine Attack Days at Month 1, 2, 3, 4, 5 and 6
- Change From Baseline in Average Number of Monthly Headache Days at Month 1, 2, 3, 4, 5 and 6
- (and 7 more...)
|
387 |
All |
20 Years to 64 Years (Adult) |
NCT01081795 |
CR013681
JNS019-JPN-02 |
|
April 2007 |
January 2009 |
January 2009 |
March 5, 2010 |
July 2, 2013 |
May 6, 2013 |
- Bunkyo, Japan
- Chitose, Japan
- Hachioji, Japan
- (and 27 more...)
|
|
| 73 |
NCT03556722 |
Not yet recruiting |
Transcranial Magnetic Stimulation in Episodic Migraine (Magnet-EM) |
|
- Device: Repetitive Transcranial Magnetic Stimulation.
- Device: Sham r-TMS
|
Interventional
|
Not Applicable |
- Universiti Putra Malaysia
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change from baseline in mean monthly migraine days.
- Change from baseline in mean monthly migraine attacks.
- Proportion of subjects with at least a 50% reduction from baseline in mean monthly migraine days.
- (and 16 more...)
|
76 |
All |
18 Years to 60 Years (Adult) |
NCT03556722 |
GPB/2017/9585500 |
Magnet-EM |
March 15, 2019 |
December 2020 |
June 2021 |
June 14, 2018 |
February 18, 2019 |
|
- University Putra Malaysia
Serdang, Selangor, Malaysia
|
|
| 74 |
NCT03521193 |
Recruiting |
Migraine Relief After Patent Foramen Ovale Closure: a Single Center Analysis |
- Platelet Aggregation, Spontaneous
- Migraine With Aura
- Patent Foramen Ovale
|
- Device: patent foramen ovale closure
|
Interventional
|
Not Applicable |
- Centro Cardiologico Monzino
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Migraine and aura
- Platelet activation
- Platelet reactivity tests
- Clinical outcomes
|
100 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT03521193 |
CCM769 |
|
February 15, 2018 |
December 30, 2019 |
June 30, 2020 |
May 10, 2018 |
May 10, 2018 |
|
- Centro Cardiologico Monzino, IRCCS
Milan, MI, Italy
|
|
| 75 |
NCT01980927 |
Completed |
Changes in Intracranial Compliance in Migraine Subjects Following a National Upper Cervical Chiropractic Association Atlas Correction |
|
- Procedure: NUCCA atlas correction
|
Interventional
|
Not Applicable |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in intracranial compliance; comparing the baseline period to one month post treatment, 4 weeks after initiation of NUCCA care and maintained correction of atlas misalignment, as measured by phase contrast magnetic resonance imaging.
- Days with headache per month
- Average headache intensity on headache days
|
11 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01980927 |
24116 |
|
November 2011 |
January 2013 |
November 2014 |
November 11, 2013 |
December 12, 2014 |
|
- Foothills Hospital
Calgary, Alberta, Canada
|
|
| 76 |
NCT03015753 |
Unknown † |
The Efficacy of Tai Chi Training for the Prophylaxis of Migraine in Chinese Women |
|
- Behavioral: Tai Chi training
- Other: Waiting list control group
|
Interventional
|
Not Applicable |
- The Hong Kong Polytechnic University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Outcomes Assessor)
- Primary Purpose: Treatment
|
- The difference in frequency of migraine attacks (the number of attacks per month)
- The proportion of responders
- Duration of headache attack
- (and 17 more...)
|
60 |
Female |
18 Years to 65 Years (Adult, Older Adult) |
NCT03015753 |
G-UA8P |
|
February 2016 |
April 2017 |
July 2017 |
January 10, 2017 |
January 11, 2017 |
|
- The Hong Kong Polytechnic University
Hung Hom, Hong Kong
|
|
| 77 |
NCT00846495 |
Completed
Has Results |
Pilot Study to Compare Frovatriptan vs. Topiramate for Prevention of Migraine |
|
- Drug: topiramate
- Drug: frovatriptan
|
Interventional
|
Phase 4 |
- Clinvest
- Endo Pharmaceuticals
- Cady, Roger, M.D.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Prevention
|
- Number of Migraine Attacks in Participants Using Frovatriptan in a Preemptive Treatment Paradigm vs. Daily Topiramate
- Number of Headache Days Reported by Participants Using Frovatriptan in a Preemptive Treatment Paradigm vs. Daily Topiramate to Prevent Migraine
- Number of Headache Days Each Month Following Initiation of Treatment With Study Medication
- (and 5 more...)
|
55 |
All |
18 Years and older (Adult, Older Adult) |
NCT00846495 |
Frova vs. Topiramate |
|
August 2009 |
January 2011 |
January 2011 |
February 18, 2009 |
January 13, 2012 |
August 9, 2011 |
- Physician Associates LLC
Oviedo, Florida, United States - Clinvest
Springfield, Missouri, United States
|
|
| 78 |
NCT00397254 |
Completed
Has Results |
Two Rizatriptan Prescribing Portions for Treatment of Migraine |
|
|
Interventional
|
Phase 4 |
- Clinvest
- Merck Sharp & Dohme Corp.
|
Other / Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
|
- Number of Days With Migraine
- Number of Migraine Attacks
- Percentage of Responders
- (and 5 more...)
|
197 |
All |
18 Years and older (Adult, Older Adult) |
NCT00397254 |
078-00 |
|
December 2006 |
January 2008 |
January 2008 |
November 9, 2006 |
June 8, 2010 |
September 22, 2009 |
- Brian Koffman, MD
Diamond Bar, California, United States - San Francisco Clinical Research Center
San Francisco, California, United States - Physician Associates
Oviedo, Florida, United States - (and 7 more...)
|
|
| 79 |
NCT02945839 |
Not yet recruiting |
Improving Health Outcomes of Migraine Patients Who Present to the Emergency Department |
|
- Drug: Preventative Medication (PM)
- Behavioral: Enhanced Usual Care
- Behavioral: PMR (progressive muscle relaxation therapy)
|
Interventional
|
Phase 4 |
- New York University School of Medicine
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Migraine Disability Assessment Scale (MIDAS) at 3 Months and Baseline
- Perceived Stress Scale (PSS)
- Number of days/week treated with acute medications
- Number of drug administrations/week for acute medications
|
90 |
All |
18 Years to 64 Years (Adult) |
NCT02945839 |
16-00548 |
|
March 2019 |
March 2019 |
March 2019 |
October 26, 2016 |
December 24, 2018 |
|
- New York University School of Medicine
New York, New York, United States
|
|
| 80 |
NCT02616978 |
Completed |
Retrospective Study on the Use of CEFALY® Device During Migraine Attacks |
|
|
Observational
|
|
|
Industry |
- Observational Model: Case-Only
- Time Perspective: Retrospective
|
- Monthly number of acute drug intake avoided when using Cefaly to treat a migraine attack
- Proportion of Cefaly users that report using also the device to treat migraine attacks
- Proportion of migraine attacks treated with the Cefaly device
- Proportion of migraine attacks for which the use of the Cefaly device generate a reduction of drug intake
|
807 |
All |
Child, Adult, Older Adult |
NCT02616978 |
50214 |
|
November 2015 |
December 2015 |
December 2015 |
November 30, 2015 |
May 8, 2017 |
|
|
|
| 81 |
NCT02174861 |
Completed
Has Results |
A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention. |
- Treatment for Prevention of Chronic Migraine
|
|
Interventional
|
Phase 2 |
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With Adverse Events
- CHU Substudy: Number of Participants Able to Administer a Full Dose of Erenumab in Home-use
- Change From Study 20120295 Baseline in Monthly Migraine Days
- (and 4 more...)
|
609 |
All |
18 Years to 66 Years (Adult, Older Adult) |
NCT02174861 |
20130255
2013-005311-27 |
|
June 30, 2014 |
May 26, 2017 |
May 26, 2017 |
June 26, 2014 |
June 19, 2018 |
June 19, 2018 |
- Research Site
Newport Beach, California, United States - Research Site
Palo Alto, California, United States - Research Site
Santa Monica, California, United States - (and 62 more...)
|
|
| 82 |
NCT02315833 |
Recruiting |
The Efficacy of L-cysteine in Prevention of Headache Attacks in Migraine Patients |
|
- Drug: Acetium
- Drug: Placebo
|
Interventional
|
Not Applicable |
- Biohit Oyj
- The Finnish Funding Agency for Technology and Innovation (TEKES)
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Number of migraine attacks (NMA) per evaluation interval
- Number of migraine days (NMD) per evaluation period
|
200 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02315833 |
AC-MIGPREV-1 |
|
June 2014 |
February 2019 |
February 2019 |
December 12, 2014 |
September 24, 2018 |
|
- Confido Privat Medical Clinic
Tallinn, Estonia - Tartu University Hospital, Neurology Clinic
Tartu, Estonia - Terveystalo, Kamppi
Helsinki, Finland - (and 4 more...)
|
|
| 83 |
NCT01972607 |
Completed |
The Effect of Aerobic Exercise Training for Migraine Prevention. |
- Headache Disorders, Primary
|
|
Interventional
|
Not Applicable |
- Federal University of São Paulo
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior.
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Prevention
|
- Frequency of Migraine/month
- Plasma levels of anandamide, cytokines and aminopeptidases
- Days with Migraine
|
60 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01972607 |
081511 |
|
March 2012 |
March 2015 |
March 2016 |
October 30, 2013 |
April 11, 2016 |
|
- Federal University of Sao Paulo
São Paulo, SP, Brazil
|
|
| 84 |
NCT02959177 |
Completed |
A Study of LY2951742 (Galcanezumab) in Japanese Participants With Episodic Migraine |
|
- Drug: Galcanezumab
- Drug: Placebo
|
Interventional
|
Phase 2 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
|
- Mean Change from Baseline in the Number of Monthly Migraine Headache Days
- Proportion of Participants with Reduction from Baseline ≥50%, ≥75% and 100% in Monthly Migraine Headache Days
- Mean Change from Baseline on the Migraine-Specific Quality of Life Questionnaire
- (and 9 more...)
|
451 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02959177 |
15796
I5Q-JE-CGAN |
|
November 9, 2016 |
January 18, 2019 |
January 18, 2019 |
November 8, 2016 |
February 19, 2019 |
|
- For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Chiba, Japan - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Chofu-shi, Japan - For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
Fukui, Japan - (and 44 more...)
|
|
| 85 |
NCT03400059 |
Recruiting |
Study to Evaluate the Efficacy of Intranasal Kinetic Oscillation Stimulation in the Preventive Treatment of Chronic Migraine |
|
- Device: Chordate System S211 in treatment mode
- Device: Chordate System S211 in placebo mode
|
Interventional
|
Not Applicable |
- Chordate Medical
- Vinnova (Swedish Governmental Agency for Innovation Systems)
- FGK Clinical Research GmbH
|
Industry / Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Mean change from Baseline (4-week screening period) in monthly headache days with moderate to severe intensity in 4-week performance assessment period (V3 to V7).
- Mean change from Baseline in monthly headache days with moderate to severe intensity in follow-up period
- Mean change from Baseline in monthly migraine days
- (and 8 more...)
|
140 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03400059 |
PM007 |
|
March 22, 2018 |
July 2019 |
July 2019 |
January 17, 2018 |
November 19, 2018 |
|
- Neurologie- & Kopfschmerzzentrum
München, Bayern, Germany - Klinikum Großhadern / Neurologische Klinik der Universität München
München, Bayern, Germany - Migräne-Klinik Königstein
Königstein Im Taunus, Hessen, Germany - (and 2 more...)
|
|
| 86 |
NCT00210821 |
Completed |
Comparing the Safety and Effectiveness of Topiramate With the Safety and Effectiveness of Amitriptyline in Preventing Migraine Headaches |
|
|
Interventional
|
Phase 3 |
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- Ortho-McNeil Neurologics, Inc.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Prevention
|
- Change from baseline in the average monthly migraine episode rate.
- Change in average monthly rate of days with migraine headache; change in average monthly rate of headache (migraine & non-migraine) days; change in average monthly rate of acute abortive medications; weight changes; quality of life assessments
|
347 |
All |
18 Years and older (Adult, Older Adult) |
NCT00210821 |
CR004666 |
|
February 2004 |
|
November 2005 |
September 21, 2005 |
June 10, 2011 |
|
|
|
| 87 |
NCT02518464 |
Active, not recruiting |
Ticagrelor Therapy for RefrACTORy Migraine Study |
- Migraine
- Headache
- Migraine Headache
|
- Drug: Ticagrelor 90 mg twice per day
|
Interventional
|
Phase 4 |
- Columbia University
- AstraZeneca
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
|
40 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02518464 |
AAAO4109 |
TRACTOR |
October 2015 |
September 2017 |
October 2017 |
August 7, 2015 |
August 16, 2017 |
|
- Columbia University Medical Center
New York, New York, United States
|
|
| 88 |
NCT00529945 |
Suspended |
PFx Closure System in Subjects With Cryptogenic Stroke, TIA, Migraine or Decompression Illness |
- PFO
- Stroke
- Transient Ischemic Attack
- (and 2 more...)
|
- Device: PFx Closure System
|
Interventional
|
Not Applicable |
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- PFO closure at 6 months post procedure.
- PFO closure at 30 days and 12 months post procedure. AE event rate for all subjects. Measurement of migraine severity or frequency at 6 and 12 months post procedure for subjects enrolled due to diagnosis of migraine.
|
200 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT00529945 |
CA0012 |
Paradigm IV |
August 2007 |
|
December 2007 |
September 14, 2007 |
December 21, 2007 |
|
- Cardiovascular Center Frankfurt Sankt katharinen
Frankfurt, Germany
|
|
| 89 |
NCT01357031 |
Completed |
Study With Amitriptylin to Evaluate the Efficacy of Melatonin in Treatment of Migraine |
|
- Drug: Amitriptyline
- Drug: Melatonin
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Hospital Israelita Albert Einstein
- Fundação de Amparo à Pesquisa do Estado de São Paulo
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change in number of headache days from baseline to month 3 after treatment.
- Proportion of patients responding to treatment. Change from Baseline Phase to Double-Blind Phase in number of monthly migraine attacks, migraine intensity, migraine duration, analgesic use, weight (in kg), and tolerability reports.
|
192 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01357031 |
EDUMAP |
EDUMAP |
May 2010 |
December 2011 |
December 2012 |
May 20, 2011 |
December 30, 2015 |
|
- Instituto Israelita de Ensino e Pesquisa Albert Einstein
São Paulo, Brazil
|
|
| 90 |
NCT00236561 |
Completed |
A Study of the Efficacy and Safety of Two Doses of Topiramate Compared to Placebo and Propranolol in the Prevention of Migraine |
- Migraine
- Common Migraine
- Classic Migraine
- Headache
|
- Drug: topiramate, propranolol
|
Interventional
|
Phase 3 |
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Change in the monthly (28 days) migraine period rate from the Prospective Baseline Period to the Core Double-Blind Phase.
- Proportion of patients responding to treatment.Change from Baseline Phase to Core Double-Blind Phase in number of monthly migraine attacks,monthly migraine days, number of days/month requiring rescue medication,and Health Related Quality of Life measures
|
786 |
All |
12 Years to 65 Years (Child, Adult, Older Adult) |
NCT00236561 |
CR003205 |
|
April 2001 |
|
December 2002 |
October 12, 2005 |
November 19, 2010 |
|
|
|
| 91 |
NCT00210535 |
Completed |
A Study of the Effectiveness and Safety of Topiramate for the Prevention of Migraine Attacks in Children |
- Migraine
- Vascular Headaches
|
- Drug: Topiramate; Placebo
|
Interventional
|
Phase 3 |
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Percent reduction in the frequency of monthly migraine attacks (using 48-hour rule) over the last 12 weeks of the double-blind treatment phase compared with the 4-week prospective baseline period.
- Percent reduction in (a) average monthly migraine days, (b) average monthly headache days, and (c) monthly migraine rate, over the last 12 weeks of the double-blind treatment phase compared with the prospective baseline period.
|
110 |
All |
12 Years to 17 Years (Child) |
NCT00210535 |
CR002245 |
|
June 2005 |
|
November 2006 |
September 21, 2005 |
June 8, 2011 |
|
|
|
| 92 |
NCT03777059 |
Recruiting |
To Evaluate the Safety and Tolerability of Atogepant 10mg, 30 mg and 60 mg Once a Day for the Prevention of Migraine in Participants With Episodic Migraine |
|
- Drug: Atogepant 30 mg
- Drug: Atogepant 60 mg
- Drug: Placebo
- Drug: Atogepant 10 mg
|
Interventional
|
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Change from baseline in mean monthly migraine days across the 12-week treatment period
- Change from baseline in mean monthly headache days across the 12-week treatment period.
- Change from baseline in mean monthly acute medication use days across the 12-week treatment period.
- (and 3 more...)
|
872 |
All |
18 Years to 80 Years (Adult, Older Adult) |
NCT03777059 |
3101-301-002 |
|
December 14, 2018 |
February 5, 2020 |
February 5, 2020 |
December 17, 2018 |
January 25, 2019 |
|
- Barrow Neurological Institute
Phoenix, Arizona, United States - Mayo Clinic Scottsdale
Scottsdale, Arizona, United States - Orange Grove Family Practice
Tucson, Arizona, United States - (and 85 more...)
|
|
| 93 |
NCT02629861 |
Completed
Has Results |
Efficacy and Safety of 2 Dose Regimens of TEV-48125 Versus Placebo for the Preventive Treatment of Episodic Migraine |
|
- Drug: Fremanezumab
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Teva Branded Pharmaceutical Products, R&D Inc.
- Teva Pharmaceutical Industries
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline in the Monthly Average Number of Migraine Days During the 12-Week Period After the First Dose of Study Drug
- Participants With Adverse Events
- Percentage of Participants With At Least 50% Reduction In Monthly Average Number of Migraine Days During the 12-Week Period After the First Dose of Study Drug
- (and 11 more...)
|
875 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT02629861 |
TV48125-CNS-30050
2015-004598-34 |
|
March 23, 2016 |
April 10, 2017 |
April 10, 2017 |
December 14, 2015 |
November 8, 2018 |
November 8, 2018 |
- Teva Investigational Site 13628
Birmingham, Alabama, United States - Teva Investigational Site 13577
Birmingham, Alabama, United States - Teva Investigational Site 13577
Birmingham, Alabama, United States - (and 272 more...)
|
|
| 94 |
NCT00231595 |
Completed |
A Study of the Efficacy and Safety of Topiramate in the Prevention of Migraine |
- Migraine
- Common Migraine
- Classic Migraine
- Headache
|
|
Interventional
|
Phase 3 |
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
|
- Change in monthly (28 day) migraine period rate from the prospective baseline period to the double-blind phase.
- Proportion of patients responding to the treatment. Changes from baseline to the double-blind phase in number of monthly migraine attacks, monthly migraine days, number of days/month requiring rescue medication and Health-Related Quality of Life measures
|
768 |
All |
12 Years to 65 Years (Child, Adult, Older Adult) |
NCT00231595 |
CR003208 |
|
March 2001 |
|
November 2002 |
October 4, 2005 |
November 19, 2010 |
|
|
|
| 95 |
NCT01389193 |
Completed |
Ibudilast in the Treatment of Patients With Chronic Migraine. |
|
- Drug: Ibudilast
- Drug: Placebo
|
Interventional
|
Phase 1 |
- Parisa Gazerani
- The Ministry of Science, Technology and Innovation, Denmark
- Migraine Research Foundation
- Aalborg University
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Basic Science
|
- Primary efficacy end point
- Secondary efficacy end points
- Serum biomarker levels
|
33 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT01389193 |
IBU-003
MRF and DRC |
IBU-003 |
June 2013 |
December 2015 |
December 2015 |
July 8, 2011 |
December 29, 2015 |
|
- School of Medical sciences, University of Adelaide
Adelaide, Australia
|
|
| 96 |
NCT02621931 |
Completed
Has Results |
Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine |
|
- Drug: Fremanezumab
- Drug: Placebo
|
Interventional
|
Phase 3 |
- Teva Branded Pharmaceutical Products, R&D Inc.
- Teva Pharmaceutical Industries
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
|
- Change From Baseline in the Monthly Average Number of Headache Days of At Least Moderate Severity During the 12-Week Period After the First Dose of Study Drug
- Participants With Treatment-Emergent Adverse Events (TEAEs)
- Change From Baseline in the Monthly Average Number of Migraine Days During the 12-Week Period After the First Dose of Study Drug
- (and 12 more...)
|
1130 |
All |
18 Years to 70 Years (Adult, Older Adult) |
NCT02621931 |
TV48125-CNS-30049
2015-004549-23 |
|
March 22, 2016 |
April 11, 2017 |
April 11, 2017 |
December 4, 2015 |
December 6, 2018 |
December 6, 2018 |
- Teva Investigational Site 13628
Birmingham, Alabama, United States - Teva Investigational Site 13577
Birmingham, Alabama, United States - Teva Investigational Site 13577
Birmingham, Alabama, United States - (and 270 more...)
|
|
| 97 |
NCT02532023 |
Unknown † |
The Combined Effects of omega3 Fatty Acids and Curcumin Supplementation on Inflammatory and Endothelial Factors in Migraine Patients |
|
- Dietary Supplement: omega 3 fatty acid
- Dietary Supplement: curcumin
- Dietary Supplement: omega 3 fatty acid placebo
- Dietary Supplement: curcumin placebo
|
Interventional
|
Phase 4 |
- Tehran University of Medical Sciences
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Supportive Care
|
- headache attack
- serum COX-2
- serum iNOs
- (and 15 more...)
|
80 |
All |
20 Years to 50 Years (Adult) |
NCT02532023 |
28825 |
|
September 2015 |
September 2016 |
February 2017 |
August 25, 2015 |
August 25, 2015 |
|
|
|
| 98 |
NCT02122757 |
Unknown † |
Anodal Transcranial Direct Current Stimulation of the Visual Cortex Versus Sham Stimulation in the Episodic Migraine |
|
|
Interventional
|
Phase 3 |
- University Hospital of Liege
|
Other |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
|
- Migraine frequency
- Migraine intensity
- Acute medication intake
- (and 2 more...)
|
30 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT02122757 |
CB-1300 |
ANODEM |
September 2013 |
September 2015 |
September 2015 |
April 25, 2014 |
May 28, 2015 |
|
- Roberta Baschi
Liege, Belgium
|
|
| 99 |
NCT03132233 |
Recruiting |
Energy for the Brain |
- Migraine
- Episodic Migraine
|
- Dietary Supplement: Beta-hydroxybutyrate calcium and magnesium salt
- Other: placebo powder
|
Interventional
|
Not Applicable |
- University Hospital, Basel, Switzerland
|
Other |
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
|
- Number of migraine days
- Number of headache days
- Acute migraine medication
- (and 3 more...)
|
45 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03132233 |
MigraKet |
MigraKet |
May 8, 2017 |
July 31, 2019 |
July 31, 2019 |
April 27, 2017 |
October 2, 2018 |
|
- University Children's Hospital (UKBB)
Basel, Basel-Stadt, Switzerland
|
|
| 100 |
NCT03828539 |
Not yet recruiting
New |
Head-to-head Study of Erenumab Against Topiramate in Patients With Episodic Migraine |
|
- Biological: Erenumab
- Drug: Topiramate
|
Interventional
|
Phase 4 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
|
- Number of patients discontinuing treatment due to AE during the double-blind epoch of the study
- Percentage of patients with a 50% response in the reduction of Monthly Migraine Days
|
700 |
All |
18 Years to 65 Years (Adult, Older Adult) |
NCT03828539 |
CAMG334ADE01 |
HER-MES |
February 28, 2019 |
June 17, 2020 |
June 17, 2020 |
February 4, 2019 |
February 4, 2019 |
|
|
|
Create an RSS feed from your search for:
Download the search results for: